Kidney transplantation
Drug research and approvals for kidney transplantation: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 254 studies of kidney transplantation are recruiting on ClinicalTrials.gov, Health Canada has authorized 23 drug trials for it since 2013, and FDA has 0 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 254
- Trials authorized in Canada: 23
- FDA orphan approvals: 0
- EU medicines: 0
- Bone Deterioration After Kidney Transplantation Assessed by DXA and HR-pQCTNCT07935915 · Not reported · Medical University Innsbruck · starts Oct 21, 2026
- Evaluation of the Outcomes of Kidney Biopsies in Deceased Donors in the Emilia-Romagna RegionNCT07932457 · Not reported · IRCCS Azienda Ospedaliero-Universitaria di Bologna · starts Oct 1, 2025
- Il Registro Italiano di Dialisi Pediatrica (RIDP) - Italian Registry of Pediatric DialysisNCT07918066 · Not reported · Istituto Giannina Gaslini · starts Jan 29, 2024
- A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in…NCT07898774 · Phase 3 · Swedish Orphan Biovitrum · starts Jan 21, 2027
- Multidisciplinary Non-Pharmacological Intervention to Improve Quality of Life in Solid Organ Transplant RecipientsNCT07870811 · Not applicable · The Mediterranean Institute for Transplantation and Advanced Specialized Therapies · starts Apr 27, 2026
- Hypothermic Machine Perfusion With Omnisol of Deceased Donor Kidneys Prior to TransplantationNCT07792317 · Not applicable · Vivalyx GmbH · starts Nov 17, 2025
- China Glomerulonephritis Kidney Transplant Recipient Cohort: A Prospective Multicenter Observational StudyNCT07783737 · Not reported · AstraZeneca · starts Oct 1, 2026
- Effects Of Propofol And Sevoflurane On Plasma Mirna Levels İn Living Kidney DonorsNCT07760402 · Not applicable · University of Gaziantep · starts May 1, 2026
- The Impact of Intraoperative Diuretic Use on Delayed Graft Function Following Deceased Donor Renal TransplantationNCT07726134 · Not applicable · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · starts Sep 1, 2026
Approved 6
- BelataceptT-lymphocyte activation antigen CD86 inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- BasiliximabInterleukin-2 receptor inhibitor
- DaclizumabInterleukin-2 receptor inhibitor
- ImlifidaseAntibodies hydrolytic enzyme
Phase 1 or earlier 1
- IscalimabTumor necrosis factor receptor superfamily member 5 inhibitor
| Aug 27, 2026 | A multicenter, phase 3 randomized, active-controlled, open-label study to evaluate the efficacy and safety of tegoprubart compared with tacrolimus in adult…Tegoprubart (AT-1501) | Eledon Pharmaceuticals | Pending |
| Aug 24, 2026 | An adaptive, randomised controlled trial to treat polyomavirus infections (BKPYV) in kidney and kidney-pancreas transplant recipientsGamunex / Igivnex | University of Queensland | Pending |
| Feb 25, 2026 | Advancing transplantation outcomes in childrenNulojix / Rapamune | National Institute of Allergy and Infectious Diseases (Niaid) | Ongoing |
| Jan 6, 2026 | Renal ex vivo SYN002 perfusion to eliminate cmv transmission: a pilot safety trial in kidney transplant recipients. (short title: respect-cmv trial)SYN002 | University Health Network Ajmera Transplant Centre | Pending |
| Nov 26, 2025 | A seamless phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant and safety of…Frexalimab (SAR441344) | Sanofi-Aventis Canada Inc | Ongoing |
| Oct 30, 2025 | A double-blind, placebo-controlled, multicenter, randomized phase 2 trial evaluating the efficacy and safety of felzartamab in recipients of kidney transplants…Felzartamab | Biogen | Ongoing |
| Jun 19, 2025 | A phase 2b, non-randomized, controlled, open-label, extension study to evaluate the persistence of immune response of the adjuvanted rsvpref3 vaccine and the…Bio RSV oa=adj (GSK3844766A) | GSK | Ongoing |
| Apr 16, 2025 | Semaglutide for the prevention of post-transplant diabetes mellitus in kidney transplant recipientsRybelsus (semaglutide) | University Health Network | Ongoing |
| Feb 11, 2025 | A phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of ravulizumab administered intravenously in…Ultomiris [ravulizumab (ALXN1210)] | AstraZeneca Pharmaceuticals | Ongoing |
| Jun 12, 2024 | Evaluation of thiosulfate in end stage renal disease and kidney transplantationSodium thiosulfate | London Health Sciences Centre | Ongoing |
| May 31, 2023 | N-myristoylated -Glu-Ala-Val-Ser-Leu-Lys-Pro-ThrPrevention of ischemia/reperfusion injury in kidney transplantation | Young Therapeutics, LLC | Designated |
| Nov 30, 2016 | C1 esterase inhibitor (Human)Treatment of acute antibody mediated rejection following kidney transplantation | Takeda Development Center Americas, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA